MA39809A - Derives de nucleoside substitues en 4' en tant qu'inhibiteurs de la transcriptase inverse du vih - Google Patents

Derives de nucleoside substitues en 4' en tant qu'inhibiteurs de la transcriptase inverse du vih

Info

Publication number
MA39809A
MA39809A MA039809A MA39809A MA39809A MA 39809 A MA39809 A MA 39809A MA 039809 A MA039809 A MA 039809A MA 39809 A MA39809 A MA 39809A MA 39809 A MA39809 A MA 39809A
Authority
MA
Morocco
Prior art keywords
reverse transcriptase
transcriptase inhibitors
hiv reverse
substituted nucleoside
nucleoside derivatives
Prior art date
Application number
MA039809A
Other languages
English (en)
Other versions
MA39809B1 (fr
Inventor
Jianmin Fu
Vinay M Girijavallabhan
David B Olsen
Bing-Yu Tang
Zhibo Zhang
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52824598&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA39809(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of MA39809A publication Critical patent/MA39809A/fr
Publication of MA39809B1 publication Critical patent/MA39809B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/14—Pyrrolo-pyrimidine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/12—Triazine radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA39809A 2014-03-28 2015-03-26 Derives de nucleoside substitues en 4' en tant qu'inhibiteurs de la transcriptase inverse du vih MA39809B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/CN2014/074294 WO2015143712A1 (fr) 2014-03-28 2014-03-28 Inhibiteurs nucléosidiques substitués en 4' de la transcriptase inverse
PCT/US2015/022621 WO2015148746A1 (fr) 2014-03-28 2015-03-26 Dérivés nucléosidiques 4'-substitués utilisés comme inhibiteurs de la transcriptase inverse du vih

Publications (2)

Publication Number Publication Date
MA39809A true MA39809A (fr) 2021-04-07
MA39809B1 MA39809B1 (fr) 2021-10-29

Family

ID=52824598

Family Applications (1)

Application Number Title Priority Date Filing Date
MA39809A MA39809B1 (fr) 2014-03-28 2015-03-26 Derives de nucleoside substitues en 4' en tant qu'inhibiteurs de la transcriptase inverse du vih

Country Status (41)

Country Link
US (2) US9777035B2 (fr)
EP (1) EP3122752B1 (fr)
JP (1) JP6182680B2 (fr)
KR (1) KR101961009B1 (fr)
CN (1) CN106795199B (fr)
AP (1) AP2016009482A0 (fr)
AR (1) AR099788A1 (fr)
AU (2) AU2015236018B2 (fr)
CA (1) CA2943792C (fr)
CL (1) CL2016002414A1 (fr)
CR (1) CR20160451A (fr)
CY (1) CY1124829T1 (fr)
DK (1) DK3122752T3 (fr)
DO (1) DOP2016000265A (fr)
EA (1) EA031476B1 (fr)
EC (1) ECSP16085206A (fr)
ES (1) ES2894228T3 (fr)
GE (1) GEP20197009B (fr)
GT (1) GT201600201A (fr)
HR (1) HRP20211622T1 (fr)
HU (1) HUE056913T2 (fr)
IL (1) IL247923B (fr)
JO (1) JO3636B1 (fr)
LT (1) LT3122752T (fr)
MA (1) MA39809B1 (fr)
MD (1) MD4812C1 (fr)
MX (1) MX367058B (fr)
MY (1) MY194635A (fr)
NI (1) NI201600145A (fr)
NZ (1) NZ724343A (fr)
PE (1) PE20170197A1 (fr)
PH (1) PH12016501897A1 (fr)
PL (1) PL3122752T3 (fr)
PT (1) PT3122752T (fr)
RS (1) RS62418B1 (fr)
SG (1) SG11201608031PA (fr)
SI (1) SI3122752T1 (fr)
SV (1) SV2016005290A (fr)
TW (1) TWI660967B (fr)
UA (1) UA120758C2 (fr)
WO (2) WO2015143712A1 (fr)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA41213A (fr) * 2014-12-19 2017-10-24 Alios Biopharma Inc Nucléosides substitués, nucléotides et analogues de ceux-ci
US11453697B1 (en) 2015-08-13 2022-09-27 Merck Sharp & Dohme Llc Cyclic di-nucleotide compounds as sting agonists
MX2018001814A (es) 2015-08-13 2018-05-07 Merck Sharp & Dohme Compuestos dinucleotidos ciclicos como agonistas del estimulador de genes de interferon.
MX2018003212A (es) 2015-09-23 2018-07-06 Merck Sharp & Dohme Inhibidores de transcriptasa inversa de nucleosido 4'-substituido y preparaciones de los mismos.
JOP20170038B1 (ar) 2016-02-12 2021-08-17 Merck Sharp & Dohme مركبات للاستخدام لعلاج عدوى بفيروس hiv والوقاية منه
WO2017223414A1 (fr) 2016-06-24 2017-12-28 Incyte Corporation Composants hétérocycliques utilisés en tant qu'inhibiteurs de pi3k-y
CR20190168A (es) 2016-10-04 2019-05-17 Merck Sharp & Dohme Compuestos de benzo[b]tiofeno como agonistas de sting
WO2018110591A1 (fr) * 2016-12-13 2018-06-21 ヤマサ醤油株式会社 Dérivé de 2'-désoxy-7-déazapurine nucléoside ayant une activité antivirale
US11466047B2 (en) 2017-05-12 2022-10-11 Merck Sharp & Dohme Llc Cyclic di-nucleotide compounds as sting agonists
EP3661498A4 (fr) 2017-08-04 2021-04-21 Merck Sharp & Dohme Corp. Agonistes benzo[b]thiophène de sting pour le traitement du cancer
MA49773A (fr) 2017-08-04 2021-04-21 Merck Sharp & Dohme Combinaisons d'antagonistes de pd-1 et d'agonistes de sting benzo[b
CA3075950A1 (fr) 2017-09-18 2019-03-21 Janssen Biopharma, Inc. Nucleosides substitues, nucleotides et analogues de ceux-ci
EP3727401A4 (fr) 2017-12-20 2022-04-06 Merck Sharp & Dohme Corp. Composés dinucléotidiques cycliques utilisés comme agonistes sting
WO2019133712A1 (fr) * 2017-12-27 2019-07-04 Schinazi Raymond F Modalités combinées pour des nucléosides et/ou des inhibiteurs de la nadph oxydase (nox) en tant qu'agents antiviraux spécifiques de cellules myéloïdes
WO2019171285A1 (fr) * 2018-03-07 2019-09-12 Glaxosmithkline Intellectual Property (No.2) Limited Composés utiles dans la thérapie du vih
TWI793294B (zh) 2018-04-03 2023-02-21 美商默沙東有限責任公司 Sting促效劑化合物
US11702430B2 (en) 2018-04-03 2023-07-18 Merck Sharp & Dohme Llc Aza-benzothiophene compounds as STING agonists
CN112996511B (zh) 2018-07-09 2024-08-09 默沙东有限责任公司 4’-乙炔基核苷类似物的酶促合成
KR20210044806A (ko) * 2018-08-09 2021-04-23 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 Hiv 요법에 유용한 화합물
EP3914604A4 (fr) 2019-01-25 2022-10-19 Brown University Compositions et procédés pour traiter, prévenir ou inverser une inflammation et des troubles associés à l'âge
PE20212089A1 (es) * 2019-03-06 2021-11-04 Glaxosmithkline Ip No 2 Ltd Compuestos utiles en la terapia del vih
CN110054654B (zh) * 2019-05-27 2022-12-27 武汉百科药物开发有限公司 一种地西他滨中间体α-取代脱氧核糖的合成方法
AU2020346908A1 (en) * 2019-09-11 2022-03-24 The Scripps Research Institute Antiviral prodrugs and formulations thereof
WO2021116872A1 (fr) * 2019-12-09 2021-06-17 Viiv Healthcare Company Compositions pharmaceutiques contenant du cabotégravir
CN118598916A (zh) 2020-02-18 2024-09-06 吉利德科学公司 抗病毒化合物
CN112321589B (zh) * 2020-02-18 2022-05-03 山东科巢生物制药有限公司 一种抗病毒药物瑞德西韦及其中间体的合成方法
TWI794742B (zh) 2020-02-18 2023-03-01 美商基利科學股份有限公司 抗病毒化合物
TW202245800A (zh) 2020-02-18 2022-12-01 美商基利科學股份有限公司 抗病毒化合物
AU2021237718B2 (en) 2020-03-20 2023-09-21 Gilead Sciences, Inc. Prodrugs of 4'-C-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same
CN112778310A (zh) * 2020-04-20 2021-05-11 中国科学院上海药物研究所 核苷类似物或含有核苷类似物的组合制剂在抗病毒中的应用
CN113527303B (zh) * 2020-04-21 2022-06-10 浙江工业大学 一种瑞德西韦母核中间体的制备工艺
CN113637041B (zh) * 2020-05-11 2024-02-27 上海科胜药物研发有限公司 一种核糖核苷的制备方法
WO2022031894A1 (fr) 2020-08-07 2022-02-10 Gilead Sciences, Inc. Promédicaments d'analogues nucléotidiques de phosphonamide et leur utilisation pharmaceutique
CA3190702A1 (fr) 2020-08-27 2022-03-03 Elaine Bunyan Composes et methodes de traitement d'infections virales
WO2022074391A1 (fr) 2020-10-08 2022-04-14 Storm Therapeutics Limited Composés inhibiteurs de mettl3
CN112300236A (zh) * 2020-10-21 2021-02-02 佛山科学技术学院 核苷酸混合氨基磷酸酯化合物、其药物组合物及其应用
WO2022159872A1 (fr) 2021-01-25 2022-07-28 Brii Biosciences, Inc. Dérivé d'adénosine et composition pharmaceutique le comprenant
AU2022211056A1 (en) 2021-01-25 2023-07-20 Brii Biosciences, Inc. Combination therapy for hiv with adenosine derivative and capsid inhibitors
US11697666B2 (en) 2021-04-16 2023-07-11 Gilead Sciences, Inc. Methods of preparing carbanucleosides using amides
CA3228162A1 (fr) 2021-08-18 2023-02-23 Gilead Sciences, Inc. Composes phospholipidiques et leurs procedes de production et d'utilisation
IL310854A (en) 2021-08-20 2024-04-01 Shionogi & Co Nucleoside compounds and their drug derivatives possessing viral growth inhibitory activity
WO2023046900A1 (fr) 2021-09-23 2023-03-30 Katholieke Universiteit Leuven Analogues de ribonucléosides dirigés contre le sars-cov-2
US20240287124A1 (en) 2023-01-30 2024-08-29 Merck Sharp & Dohme Llc Prodrugs of 4'-substituted nucleoside reverse transcriptase inhibitors

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2073500C (fr) 1990-01-11 2008-03-25 Phillip Dan Cook Compositions et methodes pour deceler et moduler l'activite de l'arn et l'expression genique
US5681941A (en) 1990-01-11 1997-10-28 Isis Pharmaceuticals, Inc. Substituted purines and oligonucleotide cross-linking
CN1233254A (zh) 1996-10-16 1999-10-27 Icn药品公司 嘌呤l－核苷、其类似物及其用途
DE60005502T2 (de) 1999-05-12 2004-06-24 Yamasa Corp., Choshi 4'-c-ethynyl-purin-nukleoside
US6831069B2 (en) 1999-08-27 2004-12-14 Ribapharm Inc. Pyrrolo[2,3-d]pyrimidine nucleoside analogs
WO2003062256A1 (fr) 2002-01-17 2003-07-31 Ribapharm Inc. Analogues d'adenosine 2'-beta-modifiee-6-substituee et leur utilisation en tant qu'agents antiviraux
AU2003237249A1 (en) 2002-05-24 2003-12-12 Isis Pharmaceuticals, Inc. Oligonucleotides having modified nucleoside units
US20040229839A1 (en) 2003-05-14 2004-11-18 Biocryst Pharmaceuticals, Inc. Substituted nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases
WO2004106356A1 (fr) 2003-05-27 2004-12-09 Syddansk Universitet Derives de nucleotides fonctionnalises
WO2005003047A1 (fr) 2003-07-03 2005-01-13 Philips Intellectual Property & Standards Gmbh Vitre pouvant etre chauffee par une lumiere invisible
CA2502109C (fr) 2004-03-24 2010-02-23 Yamasa Corporation Derive de 2-haloadenosine avec substitution sur le carbone en position 4'
JP2009526850A (ja) 2006-02-14 2009-07-23 メルク エンド カムパニー インコーポレーテッド Ｒｎａ依存性ｒｎａウイルス感染を治療するためのヌクレオシドアリールホスホルアミデート
US7960569B2 (en) 2006-10-17 2011-06-14 Bristol-Myers Squibb Company Indole antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
US20080261913A1 (en) 2006-12-28 2008-10-23 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of liver disorders
CN101003550B (zh) * 2006-12-30 2010-05-19 河南省分析测试研究中心 8-卤代腺嘌呤类核苷化合物、合成方法和其药物用途
NZ598927A (en) 2007-01-12 2013-09-27 Biocryst Pharm Inc Antiviral nucleoside analogs
CN100532388C (zh) * 2007-07-16 2009-08-26 郑州大学 2’-氟-4’-取代-核苷类似物、其制备方法及应用
US20090318380A1 (en) * 2007-11-20 2009-12-24 Pharmasset, Inc. 2',4'-substituted nucleosides as antiviral agents
SI2937350T1 (en) 2008-04-23 2018-05-31 Gilead Sciences, Inc. 1'-SUBSTITUTED CARBON-NUCLEOUS ANALOGS FOR ANTIVIRUSAL TREATMENT
WO2010036407A2 (fr) 2008-05-15 2010-04-01 Biocryst Pharmaceuticals, Inc. Analogues nucléosidiques antiviraux
EP2313102A2 (fr) 2008-07-03 2011-04-27 Biota Scientific Management Nucléosides bicycliques et nucléotides convenant comme agents thérapeutiques
GB0815968D0 (en) 2008-09-03 2008-10-08 Angeletti P Ist Richerche Bio Antiviral agents
JPWO2010027005A1 (ja) 2008-09-05 2012-02-02 壽製薬株式会社 置換アミン誘導体及びこれを有効成分とする医薬組成物
NZ593648A (en) 2008-12-23 2013-09-27 Gilead Pharmasset Llc Nucleoside phosphoramidates
EP2376514A2 (fr) 2008-12-23 2011-10-19 Pharmasset, Inc. Analogues de nucléoside
DE102009000180A1 (de) 2009-01-13 2010-07-15 Evonik Degussa Gmbh Verfahren zur Herstellung von mehrschichtig beschichteten Gummipartikeln und mehrschichtig beschichtete Gummipartikel
GB0900914D0 (en) 2009-01-20 2009-03-04 Angeletti P Ist Richerche Bio Antiviral agents
EP2408306A4 (fr) 2009-03-20 2012-11-07 Alios Biopharma Inc Nucleoside substitue et analogues nucleotidiques
WO2011005860A2 (fr) 2009-07-07 2011-01-13 Alnylam Pharmaceuticals, Inc. Mimétiques de 5' phosphate
CA2782889C (fr) 2009-12-17 2014-08-05 Merck Canada Inc. Aminopyrimidines en tant qu'inhibiteurs de la syk
AR081428A1 (es) 2010-05-28 2012-08-29 Biocryst Pharm Inc Derivados heterociclicos condensados nitrogenados, composiciones farmaceuticas que los contienen y uso de los mismos para suprimir una respuesta inmune o tratar cancer.
SG186830A1 (en) 2010-07-22 2013-02-28 Gilead Sciences Inc Methods and compounds for treating paramyxoviridae virus infections
TW201305185A (zh) 2010-09-13 2013-02-01 Gilead Sciences Inc 用於抗病毒治療之２’－氟取代之碳－核苷類似物
EA201791916A1 (ru) * 2012-03-13 2018-07-31 Джилид Сайэнс, Инк. 2'-замещенные карбануклеозидные аналоги для противовирусного лечения
UA119050C2 (uk) * 2013-11-11 2019-04-25 Ґілеад Саєнсиз, Інк. ПІРОЛО[1.2-f][1.2.4]ТРИАЗИНИ, ЯКІ ВИКОРИСТОВУЮТЬСЯ ДЛЯ ЛІКУВАННЯ РЕСПІРАТОРНО-СИНЦИТІАЛЬНИХ ВІРУСНИХ ІНФЕКЦІЙ

Also Published As

Publication number Publication date
TWI660967B (zh) 2019-06-01
TW201619180A (zh) 2016-06-01
PE20170197A1 (es) 2017-03-22
AR099788A1 (es) 2016-08-17
ES2894228T3 (es) 2022-02-14
JO3636B1 (ar) 2020-08-27
AU2015236018B2 (en) 2017-09-28
SG11201608031PA (en) 2016-10-28
AU2015236018A1 (en) 2016-10-06
NI201600145A (es) 2016-10-27
ECSP16085206A (es) 2017-08-31
RS62418B1 (sr) 2021-10-29
PT3122752T (pt) 2021-10-20
AU2017225090B2 (en) 2018-08-09
MD4812C1 (ro) 2023-01-31
US9777035B2 (en) 2017-10-03
GT201600201A (es) 2018-12-18
CL2016002414A1 (es) 2017-05-05
WO2015148746A1 (fr) 2015-10-01
SV2016005290A (es) 2018-05-03
WO2015143712A1 (fr) 2015-10-01
CN106795199A (zh) 2017-05-31
PL3122752T3 (pl) 2022-01-03
CA2943792C (fr) 2020-02-25
SI3122752T1 (sl) 2021-11-30
CN106795199B (zh) 2020-01-10
BR112016022438A8 (pt) 2021-06-29
MD20160117A2 (ro) 2017-02-28
LT3122752T (lt) 2021-11-10
MX367058B (es) 2019-08-02
HUE056913T2 (hu) 2022-03-28
UA120758C2 (uk) 2020-02-10
DOP2016000265A (es) 2017-04-30
CA2943792A1 (fr) 2015-10-01
KR20160128437A (ko) 2016-11-07
EA031476B1 (ru) 2019-01-31
MA39809B1 (fr) 2021-10-29
MY194635A (en) 2022-12-08
GEP20197009B (en) 2019-08-12
CY1124829T1 (el) 2022-11-25
MX2016012659A (es) 2016-12-14
AU2017225090A1 (en) 2017-09-28
IL247923A0 (en) 2016-11-30
DK3122752T3 (da) 2021-10-25
NZ724343A (en) 2020-02-28
PH12016501897A1 (en) 2016-12-19
US20180002366A1 (en) 2018-01-04
EP3122752A1 (fr) 2017-02-01
MD4812B1 (ro) 2022-06-30
JP6182680B2 (ja) 2017-08-16
AP2016009482A0 (en) 2016-10-31
EA201691931A1 (ru) 2017-02-28
US20150274767A1 (en) 2015-10-01
IL247923B (en) 2021-01-31
EP3122752B1 (fr) 2021-08-25
HRP20211622T1 (hr) 2022-03-04
JP2017512797A (ja) 2017-05-25
CR20160451A (es) 2016-12-06
BR112016022438A2 (pt) 2017-08-15
KR101961009B1 (ko) 2019-03-21

Similar Documents

Publication Publication Date Title
MA39809A (fr) Derives de nucleoside substitues en 4' en tant qu'inhibiteurs de la transcriptase inverse du vih
MA40943A (fr) Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines
MA40940A (fr) Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines
MA45244A (fr) Pyridines substituées utilisées en tant qu'inhibiteurs de dnmt1
DK3302448T3 (da) Erstattede heterocyclylafledninger som cdk-inhibitore
MA41140A (fr) Dérivés de 2,4-dioxo-quinazoline-6-sulfonamide en tant qu'inhibiteurs de la parg
MA45646A (fr) Derives de benzimidazole comme des modulateurs de ror-gamma
MA47460A (fr) Aminotriazolopyridines utilisées en tant qu'inhibiteurs de kinase
MA40774A (fr) Dérivés de diaryle-urée en tant qu'inhibiteurs de kinase p38
MA46981A (fr) Dérivés de benzimidazole en tant qu'inhibiteurs de bromodomaine
DK3099775T3 (da) Vandige detergentsammensætninger
DK3389379T3 (da) Mikrobiocide phenylamidinderivater
DK3464309T3 (da) Phosphoramidatnukleosidderivater som anticancermidler
CU20160125A7 (es) Inhibidores de diacilglicerol aciltransferasa 2
BR112016018655A2 (pt) Linha de produtos de artigo absorvente
DK3642202T3 (da) Dihydro-pyrrolo-pyridin-derivater
MA46280A (fr) Inhibiteurs de la dopamine-b-hydroxylase
DK3273947T3 (da) Sammensætning for øjensundhed
DK3390412T3 (da) Vandopløselige derivater af 3,5-diphenyl-diazolforbindelser
FR3023290B1 (fr) Derives de flavaglines
DK3645513T3 (da) Benzazepinderivater
FR3037483B1 (fr) Article de portage
MA49708A (fr) Dérivés de dihétérocycle liés à cycloalkyle
DK3097076T3 (da) Hidtil ukendte cyp-eicosanoidderivater
MA54257A (fr) Plaque de platre